+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Asia-Pacific Silent Heart Attack Market 2020-2026

  • PDF Icon


  • August 2020
  • Region: Asia Pacific
  • Orion Market Research Private Limited
  • ID: 5148049
Asia-Pacific Silent Heart Attack Market Size, Share & Trends Analysis Report by Diagnosis (Electrocardiography (ECG), MRI, Computed Tomography (CT Scan), Echocardiography, and Others), by Treatment (Medication and Surgery), and by End-User (Hospitals & Clinics and Ambulatory Surgical Centers) and Forecast, 2020-2026.

Asia-Pacific silent heart attack market is estimated to grow at a CAGR of around 7.5% during the forecast period. High population base, increasing cases of heart attack, and rising awareness for cardiovascular diseases (CVDs) and other heart conditions among people are some of the major factors that are boosting the market growth in the region. Additionally, the rising healthcare expenditure and a significant rise in the standards of living are the key factors that are propelling the growth of the silent heart attack diagnosis and treatment market in the region. The developing economies of Asia-Pacific, especially China, Japan, and India are investing significantly in the development of innovative therapeutic and medical devices. Furthermore, the presence of various subsidiaries of major market players in Asia-Pacific is again estimated to boost the market growth. For instance, major companies in the market such as AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Co., have their subsidiary companies in all the major economies in the region.

Asia-Pacific silent heart attack market is segmented into diagnosis, treatment, and end-user. Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest x-ray, computed tomography (CT Scan), echocardiography, and others (blood test). Based on treatment, the market is segmented into medication and surgery. Based on end-user, the market is segmented into hospitals & clinics and ambulatory surgical centers (ASCs). Hospitals and clinics are the major end-users of devices, medications, and diagnostic tools used for the silent heart attack diagnosis and treatment. Every patient who is suffering from a silent heart attack looks for a hospital or clinic for the treatment, which boosts the demand for devices and medicines in the segment.

The companies which are contributing to the growth of the Asia-Pacific silent heart attack market include AstraZeneca PLC, Hoffmann-La Roche Ltd., Boehringer Ingelheim GmbH, Terumo Corp., and Siemens AG. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.

Research Methodology:

The market study of the Asia-Pacific silent heart attack market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, various services offered by the players, and market opportunity. The report will serve as a source for 360-degree analysis of the market delivering insights for making better business decisions.

Market Segmentation:

1. Asia-Pacific Silent Heart Attack Market Research and Analysis by Diagnosis
2. Asia-Pacific Silent Heart Attack Market Research and Analysis by Treatment
3. Asia-Pacific Silent Heart Attack Market Research and Analysis by End-User

The Report Covers:
  • Comprehensive research methodology of the Asia-Pacific silent heart attack market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Asia-Pacific silent heart attack market.
  • Insights about market determinants which are stimulating the Asia-Pacific silent heart attack market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Asia-Pacific Silent Heart Attack Market by Diagnosis
5.1.1. Electrocardiography (ECG)
5.1.2. Magnetic Resonance Imaging (MRI)
5.1.3. Computed Tomography (CT Scan)
5.1.4. Echocardiography
5.1.5. Others (Blood Test)
5.2. Asia-Pacific Silent Heart Attack Market by Treatment
5.2.1. Medication
5.2.2. Surgery Angioplasty Bypass Surgery Heart Transplant
5.3. Asia-Pacific Silent Heart Attack Market by End-User
5.3.1. Hospital & Clinics
5.3.2. Ambulatory Surgical Centers
6. Regional Analysis
6.1. China
6.2. Japan
6.3. India
6.4. Rest of Asia-Pacific
7. Company Profiles
7.1. Astellas Pharma, Inc.
7.2. AstraZeneca PLC
7.3. Bayer AG
7.4. Boehringer Ingelheim GmbH
7.5. Boston Scientific Corp.
7.6. F. Hoffmann-La Roche, Ltd.
7.7. GlaxoSmithKline Plc
7.8. Medtronic PLC
7.9. Merck & Co., Inc.
7.10. Novartis AG
7.11. Opto Circuits, Ltd.
7.12. OrbusNeich Medical Technologies
7.13. Pfizer, Inc.
7.14. Siemens AG
7.15. SLTL Group
7.16. Takeda Pharmaceutical Co., Ltd.
7.17. Terumo Corp.
7.18. Vascular Concepts, Ltd.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corp.
  • F. Hoffmann-La Roche, Ltd.
  • GlaxoSmithKline Plc
  • Medtronic PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Opto Circuits, Ltd.
  • OrbusNeich Medical Technologies
  • Pfizer, Inc.
  • Siemens AG
  • SLTL Group
  • Takeda Pharmaceutical Co., Ltd.
  • Terumo Corp.
  • Vascular Concepts, Ltd.